Direct comparison of experimental and calculated folding free energies for hydrophobic deletion mutants of chymotrypsin inhibitor 2: free energy perturbation calculations using transition and denatured states from molecular dynamics simulations of unfolding.
Previous molecular dynamics (MD) simulations of thermal denaturation of chymotrypsin inhibitor 2 (CI2) have provided transition-state models in good agreement with experiment. Unfortunately, however, the comparisons have been necessarily indirect. The simulations have provided detailed structural information but not energetics, while from experiment, structure is inferred from a ratio of free energy changes upon mutation (Phi values). Here, direct comparison with experimental free energies is obtained by performing free energy perturbation calculations of hydrophobic deletion mutants of CI2 using transition- and denatured-state structures from various denaturation MD simulations. The agreement between the calculated and experimental DeltaDeltaG and Phi values is quite good (R = 0.8-0.9). In addition, given the availability of realistic atomic models for the denatured protein, the common approach of using small peptides to represent the denatured state in stability calculations can now be evaluated. To this end, two different extended tripeptide models were used: one using the sequence from the protein with the residue to be mutated in the center and the other with this residue surrounded by Ala residues. The results for the two peptides agree neither with one another nor with the different full-length denatured-state models, which do provide results in good agreement with experiment. This finding is noteworthy because the denatured state of CI2 is very disrupted with little residual structure, such that the peptides might have been expected to serve as reasonable models. Overall the calculations presented here validate our previous MD-generated transition- and denatured-state models and therefore the simulated unfolding pathways and their relevance to refolding.
Department of Medicinal Chemistry, University of Washington, Seattle, Washington 98195-7610, USA.
Y
Y
Pan
V
V
Daggett
D000409:Alanine / Q000235:genetics; D019943:Amino Acid Substitution / Q000235:genetics; D002918:Chymotrypsin / Q000037:antagonists & inhibitors*; D003198:Computer Simulation; D005998:Glycine / Q000235:genetics; D001467:Hordeum / Q000201:enzymology; D007532:Isoleucine / Q000235:genetics; D007930:Leucine / Q000235:genetics; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D010455:Peptides; D010940:Plant Proteins / Q000737:chemistry* / Q000235:genetics*; D011489:Protein Denaturation; D017510:Protein Folding; D015203:Reproducibility of Results; D015842:Serine Proteinase Inhibitors / Q000737:chemistry* / Q000235:genetics*; D013816:Thermodynamics; D014633:Valine / Q000235:genetics
D010455:Peptides; D010940:Plant Proteins; D015842:Serine Proteinase Inhibitors; C093336:chymotrypsin inhibitor 2; D007532:Isoleucine; D002918:Chymotrypsin; D007930:Leucine; D014633:Valine; D000409:Alanine; D005998:Glycine